

August, 2025

CURRICULUM VITAE

Edward Charles Grendys Jr., M.D., FACOG, FACS

PERSONAL DATA

Place of Birth: Chicago, Illinois
Citizenship: USA

Office Address: NCH Medical Group SWFL Gynecologic Oncology
2320 Vanderbilt Beach Road
Suite 102
Naples, FL 34109

Office phone: 239-624-8080
Fax: 239-624-8081

EDUCATION:

Undergraduate: DePaul University
Chicago, Illinois
BS, 1979

Medical: Northwestern University Medical School
Chicago, Illinois
M.D., 1987

Graduate Education:

Internship:

Rush-Presbyterian St. Lukes Medical Center
Obstetrics and Gynecology
Chicago, Illinois
June, 1987 - June, 1988

Residency:

Rush-Presbyterian St. Lukes Medical Center
Obstetrics and Gynecology
June, 1988 - June, 1991

Fellowship:

Felix Rutledge Fellow
Department of Gynecologic Oncology
M.D. Anderson Cancer Center
Houston, Texas
June, 1989 - September, 1989

Georgetown University Medical Center
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Washington, D.C.
July, 1991 - July, 1994

Postdoctoral Research Training

Not Applicable

BOARD CERTIFICATION:

National Board of Medical Examiners 351045

Diplomate, American Board of Obstetrics and Gynecology December, 1996

American Board of Obstetrics and Gynecology-Gynecologic Oncology April, 1997
Recertification 2000-2025(current)

LICENSURE- Active:

Florida	ME-0072182
Federal D.E.A.	BG1586847

Medicare provider #	32707
---------------------	-------

Inactive:

Massachusetts	79194
District of Columbia	18718
Virginia	0101 047295
Maryland	D41835
Illinois	36077844

AWARDS AND HONORARY SOCIETIES:

June, 1991	Resident Teaching Award, Rush University School of Medicine
1993-1994	American Cancer Society Clinical Fellow 93381
July, 1995	Tufts Medical School, Outstanding Faculty Teaching Award
June, 1996	Residents Teaching Award, Tufts University School of Medicine
March 1998	Who's Who in Medicine and Healthcare in America
January, 2000	Who's Who in Medicine and Healthcare in America
June, 2001	Excellence in Surgical Teaching Award, University of South Florida
January, 2002	Who's Who in Medicine and Healthcare in America
June, 1999-03	Excellence in Surgical Teaching Award, University of South Florida
August, 2002	Consumers' Guide to Top Doctors
June, 2003	Association of Professors Gynecology, Obstetrics (APGO) Excellence in Teaching Award
Dec., 2003	Outstanding Faculty Teaching Award, University of South Florida
Nov, 2005	Florida Medical Association "A Physician Who Cares" award
2009	Doximetry.com Florida Super Doctor Award
2011-2024	Florida Most Recommended Physicians Award National Consumer Survey
2010-2025	Consumer Research Council "America's Top Oncologists"
2019-2025	Naples Illustrated Top Doctors

FACULTY APPOINTMENTS:

Instructor
Rush Medical School
Rush-Presbyterian St. Lukes Medical Center
Chicago, Illinois
July, 1990 - July, 1991

Instructor
Georgetown University Medical Center
Washington, D.C.
July, 1991 - June, 1994

Assistant Professor
New England Medical Center
Tufts Medical School
Boston, Massachusetts
July, 1994-December, 1996

Assistant Professor
University of South Florida, School of Medicine
Tampa, Florida
December, 1996- April, 2002

Associate Professor
University of South Florida, School of Medicine
Tampa, Florida
April, 2002 – December, 2003

Associate Professor
Northwestern University, Feinberg School of Medicine
Chicago, Illinois
December, 2003 – 2005

Faculty, Florida Gulf Coast University
March, 2024-current

Clinical Assistant Professor
Northwestern University, Feinberg School of Medicine
June, 2025-current

HOSPITAL STAFF APPOINTMENTS

Current:

Medical Director, Women's Oncology
Naples Comprehensive Health
Naples, FL

Section Chief, Gynecologic Oncology
Naples Comprehensive Health(NCH)
Naples, Florida

Lee Health System
Fort Myers, FL

Past:

Northwestern University Hospital
333 East Superior Ave
Suite 420
Chicago, IL 60656

H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Tampa General Hospital
4 Columbia Drive
Tampa, FL

University Community Hospital
3100 East Fletcher
Tampa, FL 33647

New England Medical Center
Tuft's University School of Medicine
75 Washington Street
Boston, MA 02111

ADMINISTRATIVE APPOINTMENTS

Medical Director Oncology, Naples Community Health System
Section Chief, Gynecologic Oncology, Naples Community Health System
Medical Director, Florida Gynecologic Oncology, May, 2020-current
Director, Clinical Research, Florida Gynecologic Oncology, January, 2008- October, 2025
Subsection Chief, Gyne Onc, Naples Community Hospital, Naples, FL Feb 2015-current
National Reviewer C-SATS(Crowd Sourced Assessment of Technical Skills 2018-current
Principal Investigator, Gynecologic Oncology Group(GOG), Florida Gyne Onc, Jan, 2005-current
Chairman, SGO Tumor Registry Task Force 2015-2019
Commission On Cancer Representative, SGO, 2010-2019
President, Florida Society of Gynecologic Oncology, 2010- 2012
President Elect, Florida Society of Gynecologic Oncology, 2008-, 2010
Director Gynecologic Quality Assurance, Naples Community Health System, 2008 – 2012
Interim Director Gynecologic Oncology, Northwestern University, July, 2004-November, 2004
Principal Investigator(PI)- Gynecologic Oncology Group(GOG), Northwestern University, 2004-2005
Moffitt Cancer Center Utilization Review Committee Physician Director 1997-2003
University of South Florida Institutional Review Board- Vice Chairman 1998-2003
Moffitt Cancer Center-Utilization and Information Management Committee, Chairman 2001-2003
Moffitt Cancer Center-Medical Executive Committee member at large 2001-2003

COMMITTEE SERVICE

Director Clinical Research, Lee Health System 2016-2025
Medical Staff Quality Committee, Lee Memorial Hospital, June 2017-2025
Associate Editor, AJCC 2015-current
National Reviewer C-SATS(Crowd Sourced Assessment of Technical Skills 2018-current
Society of Gynecologic Oncology- Task Force on Coding & Reimbursement Jan. ,2015-2021
Society of Gynecologic Oncology- Task Force on Policy & Quality January, 2015-2021
Society of Gynecologic Oncology, Quality and Outcomes Committee, January,2011-2015
Commission On Cancer Representative, SGO, November 2010-2019
Task Force for Cancer Treatment in the Elderly, Gynecologic Oncology Group(January, 2010-2014)
Florida Healthcare Coalition, Florida Association of Clinical Oncology- January 2010-current
Program Chair, Florida Society of Gyne Oncology annual meeting (6/2006-6/2008)
Quality Assurance Committee, Naples Community Hospital (12/2008-2014)
Cancer Committee Lee Memorial Health System (1/05-current)
Gynecologic Oncology Group (GOG)- Gynecologic Management Committee (10/94-7/2000)
Gynecologic Oncology Group (GOG)- Developmental Therapeutics Committee (11/97-1/2004)
Gynecologic Oncology Group (GOG)- Uterine Corpus Committee (12/05- 1/2011)
Ovarian Cancer Alliance of Florida- Scientific Advisory Board
University of South Florida Institutional Review Board (5/98-12/2003)
University of South Florida Institutional Review Board- Vice Chairman (10/98-12/2003)
Moffitt Cancer Center, Scientific Review Committee (5/00- 12/2003)
Moffitt Cancer Center Hospital Performance Improvement Committee (7/98-12/2003)
Moffitt Cancer Center Utilization and Information Management Committee (3/97-4/2001)
Moffitt Cancer Center Medical Records Committee (1/97-4/2001)
Moffitt Cancer Center- Library Advisory Board (6/97-12/2001)
Moffitt Cancer Center- Ethics Committee (11/97-2002)
Moffitt Cancer Center- Physicians Advisory Board (11/97-12/2003)
Moffitt Cancer Center-Chemotherapy Prescribing Peer Review Committee (4/00-2002)
Moffitt Cancer Center-Medical Executive Committee member at large (8/01-12/2003)
Interdisciplinary Oncology Program Practice Management Committee (4/2000- 12/2003)
Hillsborough County Medical Association, Continuing Education Committee (8/99-2004)
New England Medical Center Gynecologic Quality Assurance Committee (9/94-12/96)
Cancer Care Committee- St. Elizabeth's Hospital, Boston, Massachusetts (7/94-12/96)

PROFESSIONAL SOCIETIES:

Fellow, American College of Surgeons (FACS)
Fellow, American College of Obstetrics and Gynecology (ACOG)
Fellow, Society of Gynecologic Oncologists (SGO)
Fellow, Society of Surgical Oncology (SSO)
American Society of Clinical Oncology (ASCO)
American Cancer Society
Florida Medical Society
Florida Association of Clinical Oncology (FLASCO)
Florida Obstetric and Gynecologic Society
Florida Society of Gynecologic Oncologists (FSGO)
International Gynecologic Cancer Society (IGCS)

PROFESSIONAL AND SCIENTIFIC ACTIVITY

National Reviewer C-SATS (Crowd Sourced Assessment of Technical Skills 2018-current)
Reviewer- American Journal of Pathology
Reviewer- International Journal of Gynecology and Obstetrics
Reviewer- Obstetrics and Gynecology
Reviewer- Gynecologic Oncology
Reviewer- American Journal of Clinical Oncology
Guest editor- Current Opinions in Obstetric and Gynecology
Associate Editor, AJCC

SCHOLARLY PRODUCTIVITY

Refereed Journal Articles:

1. Choroidal Metastasis From Primary Ovarian Carcinoma, **Grendys EC**, Tang RA, Gershenson DM, Gynecologic Oncology 46,251-254(1992)
2. Prognostic Significance of Polymerase Chain Reaction Detected Human Papillomavirus of Tumors and Lymph Nodes in Surgically Treated Stage IB Cervix Cancer; Burnett, AF, Barnes, WA, Johnson, JC, **Grendys, EC**, Willett, GD, Barter, JF, Doniger, J, Gynecologic Oncology 47(3),343-347(1992)
3. Prognostic Factors and Long Term Survival in Endometrial Adenocarcinoma with Cervical Involvement, Boente, M, Yordan, E, **Grendys, EC**, et al., Gynecologic Oncology 1(3),316-322(1994)
4. Insertion of Groshong Central Venous Catheters Utilizing Fluoroscopic Techniques, Burnett, AF, **Grendys, EC**, Barth, KH, et al., Gynecologic Oncology 52(1),69-73(1994)
5. Identification of H,K, and N-ras Point Mutations in Stage IB Squamous Cell Carcinoma of the Cervix, **Grendys, EC**, Barnes, WA, Sparkowski, J, Schlegel, R, Gynecologic Oncology 65, 343-347(1997)
6. Preservation of Multiple Oncogenic Human Papillomavirus Types in Recurrences of Early Stage Cervical Cancers, Burnett, AF, **Grendys, EC**, Willett, GD et al.: American Journal of Obstetrics and Gynecology 170:1230-3(1993)
7. Spontaneous Internal Jugular and Subclavian Vein Thrombosis Associated with a Synchronous Ovarian and Endometrial Malignancy; Hines, JF, **Grendys, EC**, Tucker, A, Barter, JF et al., Gynecologic Oncology 56, 298-301(1995)
8. A Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced or Recurrent Adenocarcinoma of the Endometrium, Sutton, GP, Blessing, JA, DeMars, LR, Moore, D, Burke, TW, **Grendys, EC**, Gynecologic Oncology 63(1), 25-28(1996).
9. Gynecologic Oncology: Progress not withstanding (editorial), **Grendys, EC**, Current Opinion in Obstetrics and Gynecology, 1998, 10:No 1, Feb. 1998, 1-2
10. Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism, **Grendys, EC**, Fiorica, JV: Current Opinion in Obstetrics and Gynecology, 1999, 11:No. 1, 71-79

11. Alternative Care Medicine: A Time to Learn(editorial), **Grendys, EC**, Current Opinion in Obstetrics and Gynecology, 1999, 11: No. 1, 1-2
12. Innovations in the Management of Vulvar Carcinoma, **Grendys, EC**, Fiorica, JV, Current Opinion in Obstetrics and Gynecology, 2000, 12:15-20
13. Reproductive Technology and the Risk of Ovarian Carcinoma, Wakeley, KE, **Grendys, EC**, Current Opinion in Obstetrics and Gynecology, 2000, 12:43-47
14. The *HRAS1* Minisatellite Locus and Risk of Ovarian Cancer, Weitzel, JN, Ding, S, Larson, GP, Nelson, RA, Goodman, A, **Grendys, EC**, Ball, HG, Krontiris, TG, Cancer Research, 60:Jan 2000
15. Comprehensive geriatric assessment in older cancer patients undergoing chemotherapy: results from a prospective pilot study. Chen, H. Cantor, AB, Corcoran, MB, Meyer, J **Grendys, E**, Cavanaugh, D, Antonek, S, Vann, V, Cammarata, A, Haley, WE, Balducci, L, Exterman, M, Journal of the American Geriatrics Society, 48:S57, 2000
16. Lymphoscintigraphy in Cervical Cancer. Cardosi, RJ, **Grendys, EC**, Fiorica, JV, Journal of Pelvic Surgery, Vol 7, No. 6, 354-357, 2001
17. Bartholin's Gland Carcinoma: A Fifteen Year Experience, Cardosi, RJ, Speights, A, Hakam, A, **Grendys, EC**, Hoffman, MS, Gynecologic Oncology, 82, 247-251(2001)
18. Cancer & Folie a deux: A Case Report, Treatment and Implications, Sanjurjo-Hartman, T, Weitzner, MA, Santana, C, Devine, C, **Grendys, EC**, Cancer Practice, Vol. 9, No. 6, 2001
19. Intraoperative Radiolocalization of the Sentinel Node in Patients with Vulvar Cancer, Fiorica, J, **Grendys, EC**, Hoffman, M, Vol 6, No. 1 (January), 2001: pg 27-32
20. Predictors of Tolerance to Chemotherapy in Older Cancer Patients: a Prospective Pilot Study, Extermann, M, Chen, H, Cantor, AB, Corcoran, MB, Meyer, J, **Grendys, EC**, Cavanaugh, D, Antonek, S, Vann, V, Camarata, A, Haley, WE, Balducci, L, European Journal of Cancer, 38(2002) 1466-1473
21. Phase II Trial of Topotecan and Cisplatin in Persistent or Recurrent Squamous and Nonsquamous Carcinomas of the Cervix, Fiorica, J, Holloway, R, Ndubisi, B, Orr, J, **Grendys, EC**, Boothby, R, DeCesare, S, LaPolla, J, Hoffman, M, Patel, J, Gynecologic Oncology, Vol. 85, Number 1, April 2002

22. What is the Role of Interval Blood Testing in the Management of Chemotherapy for Gynecologic Malignancies, Cardosi, R, **Grendys, EC**, Eur J. Gynaec. Oncol XXIII,n.6, 2002
23. Can Older Cancer Patients Tolerate Chemotherapy? A Prospective Pilot Study, Chen, H, Cantor, A, Meyer, J, **Grendys, EC**, et al. Cancer, Feb 15, 2003, Volume 97 / Number 4
24. Infectious urinary tract morbidity with prolonged bladder catheterization after radical hysterectomy, Cardosi, RJ, **Grendys, EC**, Fiorica, JV, Hoffman, MS, Am J Obstet Gynecol. 2003, Aug; 189(2):380-3
25. Accuracy of pelvic examination in the assessment of patients with operable cervical carcinoma, Hoffman, MS, Cardosi, RJ, Roberts, WS, Fiorica, JV, **Grendys, EC**, Griffin, D, Am J Obstet Gynecol. 2004 Apr;190(4):986-93.
26. Value of multilevel sectioning for improved detection of micrometastases in sentinel lymph nodes in invasive squamous cell carcinoma of the vulva, Hakam, A, Nasir, A, Raghuwanshi, R, Smith, PV, Crawley, S, Kaiser, HE, **Grendys, EC**, Fiorica, JF, Anticancer Res, 2004 Mar-Apr, 24(2C): 1281-6
27. Relationship of Hemoglobin Levels to Fatigue and Cognitive Functioning Among Cancer Patients Receiving Chemotherapy, Jacobsen, PB, Garland, LL, Booth-Jones, M, Thors, CL, Winters, E, **Grendys, EC**, Journal of Pain and Symptom Management, Vol. 28, No. 1, July,2004; 7-18
28. Lysophospholipids are potential biomarkers of ovarian cancer, Sutphen R, Xu Y, Wilbanks GD, Fiorica J, **Grendys EC**, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP, Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91
29. National Comprehensive Cancer Network (NCCN): Ovarian Cancer Clinical Practice Guidelines, Morgan, R, Alvarez, R, Armstrong, D, Copeland, L, Fiorica, J, Fowler, J, Gaffney, D, Gershenson, D, Greer, B, **Grendys, EC**, Mohnsto, C, Lele, S, Matulonis, U, Molpus, K, Ozols, R, Sabbatine, P, Santoso, J, Soper, J, Teng, N, JNCI, Volume 2, Number 6, November, 2004 526-547
30. The Administration of Chemotherapy in a Patient with Charcot-Marie-Tooth and Ovarian Cancer, Martino, M, Miller, E, **Grendys, EC**, Gynecol Oncol, 97(2005); 710-712
31. Randomized Phase III trial of Cisplatin with or Without Toptecan in Carcinoma of the Uterine Cervix:A Gynecologic Oncology Group Study. Long, HJ, Bundy, BN, **Grendys,**

- EC**, Benda, JA, McMeekin, DS, Sorosky, J, Miller, DS, Eaton, LA, Fiorica, JV, J Clin Oncol. 2005 Jul 20;23(21):4626-33
32. A Phase II Evaluation of Flavopiridol in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study, **Grendys, EC**, Blessing, JA, Burger, R, Hoffman, J, Gyne Oncol, 98(2005) 249-253
 33. Sites of Bowel Resected to Achieve Optimal Ovarian Cancer Cytoreduction: Implications Regarding Surgical Management, Hoffman, MS, Griffin, D, Tebes, S, Cardosi, RJ, Martino, MA, Fiorica, JV, **Grendys, EC**, Amer J of Ob/Gyne, vol 193, Issue 2, 582-586, August, 2005
 34. Radical Hysterectomy versus Extrafascial Hysterectomy in the Management of Stage II Endometrial Carcinoma, Tebes, SJ, Cardosi, RJ, Hoffman, MS, **Grendys, EC**, Journal of Gynecologic Surgery, 2005;21(3), 111-116
 35. Clinical results and quality of life analysis for the MVAC combination in carcinoma of the uterine cervix: A Gynecologic Oncology Group study Long, HJ, Monk, BJ, Huang, HQ, **Grendys, EC**, Sorosky, J, Miller, DS, Eaton, LA, Fiorica, JV, Gyne Onc 100(2006) 537-543
 36. Subcutaneous management of vertical incisions with 3 or more centimeters of subcutaneous fat, Cardosi, RJ, Drake, J, Holmes, S, Tebes, SJ, Fiorica, JV, Roberts, WS, **Grendys, EC**, Am J Obstet Gyne, 2006 Aug;195(2):607-14
 37. Impact of Genetic Testing on Cancer Care: Letter to the Editor, Escobar, PF, Orr, JW, **Grendys, EC**, Roland, PY, Int. Journal of Gyne Cancer, 2007, Nov 6
 38. Ureteroarterial Fistulas After Radical Pelvic Surgery: Pathogenesis, Diagnosis and Therapeutic Modalities, Escobar, PF, Howard, J, Kelly, J, Roland, PY, Dosoretz, DE, Orr, JW, **Grendys, EC**, Int J Gynecol Cancer. 2007 Nov 6
 39. Weekly Topotecan for Recurrent Platinum Resistant Ovarian Cancer, Abushahin, F, Singh, D, Lurain, J, **Grendys, EC**, Rademak, AW, Schink, JC, Gyne Onc, 108(2008): 53-57
 40. Ovarian Cancer at young age: the contribution of mismatch-repair defects in a population based series of epithelial ovarian cancer before age 40, Escobar, PF, Orr, JW, **Grendys, EC**, Roland, PY, Int J Gynecol Cancer, 2008, Jul-Aug; 18(4):876-7
 41. Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in combination with Carboplatin Versus Gemcitabine-Carboplatin for the Treatment of Platinum

- Sensitive Recurrent Ovarian Carcinoma, Holloway, RW, **Grendys, EC**, Lefevre, P, Vekeman, F, McMeekin, S, The Oncologist, 2010, 15,
42. Stereotactic body radiation therapy as an emerging ablative therapy for recurrent gynecologic cancer: Early disease and quality of life outcomes from a phase II trial, C. Mantz, F. AbuShahin, E. Grendys, J. Orr; Gynecologic Oncology Vol 125, Supplement1, March 2012, Pages S126
 43. A Prospective Study Evaluating the Clinical Relevance of a Chemoresponse Assay for Treatment of Patients with Persistent or Recurrent Ovarian Cancer, Rutherford, T, Orr, J, **Grendys, EC**, et al Gynecologic Oncology, Vol 131, Issue 2, Nov 2-13, p 362-367
 44. In vitro chemoresponse in Metachronous Pairs of Ovarian Cancers, Dalton, HJ, Edwards, RP, Benjamin, I, Rocconi, RP, Recio, FO, Lovecchio, JL, Burrell, MO, Shahin, MH, **Grendys, ED**, Wang, D, Wang, T, Monk, BJ, AntiCancer Res, 2014, Dec;34(12):7191-6
 45. Overview of Chemoresponse Assay in Ovarian Cancer, **Grendys, EC**, Fiorica, JV, Orr, JW, Holloway, R, Wang, D, Tian, C, Chan, JK, Herzog, TJ, Clin Transl Oncol, 2014 Sep;16(9):761-9
 46. Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things, Dewdney, SB, Dancisak, AC, Lachance, JA **Grendys, EC**, Dowdy, SC, Powell, M, Schorge, JO Gynecol Oncol 2018 Mar;148(3) 439-444
 47. Use of wire guided localization for resection of recurrent, oligometastatic gynecologic clear cell carcinoma to anterior abdominal wall, Womack, H, AbuShahin, F, **Grendys, EC**, Gynecol Oncol 2022 Jul;19;42

Books and Book Chapters:

1. Gestational Trophoblastic Disease in Laboratory Medicine in Obstetrics and Gynecology; **Grendys, EC**, Barnes, WA, Barter, JF edited by Willett, GD, Blackwell Scientific Publications, Inc., 1994
2. Pelvic Masses in Pregnancy; **Grendys, EC**, Barnes, WA, edited by Delgado, G in Surgical Clinics of North America, Feb 1995,75:1-12
3. Radioguided Surgery and Vulvar Carcinoma; **Grendys, EC**, Fiorica, JV, edited by Whitman, ED in Handbook of Sentinel Lymph Node Mapping and Biopsy, Landes Bioscience, Austin, TX., 1999: pgs. 142-152
4. Lymphatic Mapping in Gynecologic Malignancies, **Grendys, EC**, Salud, C, Durfee, JK, Fiorica, JV, edited by Reintgen, D in Surgical Clinics of North America, Volume 8, No. 3, 541-553, July, 1999
5. Pregnancy and Neoplastic Disease, **Grendys, EC**, in Cecil's Textbook of Medicine, 21st edition, edited by Goldman, L, Bennett, JC, WB Saunders Company, Philadelphia, PA, 2000:pgs. 1344-1350
6. Epithelial Ovarian Carcinoma, **Grendys, EC**, Moffitt Cancer Center: 2000 Cancer Registry Annual Report, 2001
7. Pregnancy and Neoplastic Disease, **Grendys, EC**, in Cecil's Textbook of Medicine, 22nd edition, edited by Goldman, L, Bennett, JC, WB Saunders Company, Philadelphia, PA, 2004
8. Pregnancy and Neoplastic Disease, **Grendys, EC**, in Cecil's Textbook of Medicine, 23rd edition, edited by Goldman, L, Bennett, JC, WB Saunders Company, Philadelphia, PA, 2007

Exhibits and audio visual material

1. Creatinine Clearance as a Guide to Cisplatin Based Chemotherapy: Can a 24 Hour Urine Collection Be Eliminated? **Grendys, EC**, Yordan, E, Wilbanks, G, Rawlins, R, Morris, M: Rush-Presbyterian St. Lukes Medical Center, May, 1991 Chicago, Illinois; presented from podium
2. Prognostic Factors and Long-term Survival in Stage II Endometrial Carcinoma, Boente, M, **Grendys, EC**, Yordan, E, Wilbanks, G: International Gynecologic Cancer Society, September, 1991, Cairns, Australia; presented from podium
3. Human Papillomavirus in HIV Seropositive Women: The Effect of Immune Status on Viral Detection, **Grendys, EC**, Burnett, A, Johnson, J, Barter, J, Barnes, W, Doniger, J: Mid Atlantic Gynecologic Oncology Society, (MAGOS) October, 1991, Ocean City, Maryland; presented from podium
4. Creatinine Clearance as a Guide to Cisplatin Based Chemotherapy: Can a 24 Hour Urine Collection Be Eliminated? , **Grendys, EC**, Yordan, E, Wilbanks, G, Rawlins, R, Morris, M: International Gynecologic Cancer Society, September, 1991, Cairns, Australia; presented as poster
5. HPV 18 as a Risk Factor for Recurrence of Surgically Treated Stage IB Cervical Cancer in Patients with Histologically Negative Lymph Nodes.-Burnett, A, **Grendys, EC**, Doniger,J,Barnes,W:11thAnnual Papilloma Workshop,October,1992, Edinburgh, Scotland; presented as poster
6. Groshong Central Line Placement Under Fluoroscopy-Burnett, A, **Grendys, EC**, Johnson, J, Barter, J, Barnes, W; Mid-Atlantic Gynecologic Oncology Society (MAGOS), October, 1992,presented from podium
7. Inefficacy of Continuos Infusional 5-Fluorouracil for Refractory Ovarian Cancer-Burnett, A, Barter, J, Hines, J, **Grendys, EC**, Barnes, W; Mid-Atlantic Gynecologic Oncology Society (MAGOS), October, 1992, presented from podium
8. Prognostic Significance of HPV in Histologically Negative Lymph Nodes- Burnett, A, Barnes, W, Johnson, J, **Grendys, EC**, Willett, G, Barter, J, Doniger, J; American College of Obstetrics and Gynecology District IV Annual Meeting (ACOG), 1992, presented from podium
9. Human Papillomavirus 18 as a Risk Factor for Recurrent Cervical Cancer-Burnett, A, Barnes, W, Johnson, J, **Grendys, EC**, Willett, G, Barter, J, Doniger, J; Society of Gynecologic Oncology (SGO), February,1993, presented as poster

10. Increased HPV Replication in Immunocompromised HIV Infected Women-Burnett, A, Barnes, W, Johnson, J, **Grendys, EC**, Willett, G, Barter, J, Doniger, J; Society of Gynecologic Oncology, February, 1993, presented as poster
11. Preservation of Oncogenic HPV Types in Recurrences of Early Stage Cervical Carcinomas, Moore, JL, Burnett, AF, **Grendys, EC**, Willett, GD, Johnson, JC, Barter, JF, Barnes, WA, Mid-Atlantic Gynecologic Oncology Society (MAGOS), September, 1993, presented from podium
12. H, K, and N-ras Point Mutations in Cervical Carcinoma, **Grendys, EC**, Barnes, WA, Sparkowski, J, Schlegel, R, Mid-Atlantic Gynecologic Oncology Society (MAGOS), September, 1993, presented from podium
13. Long Term in-vitro Culture of Normal Ovarian and Peritoneal Coelomic Epithelium: **Grendys, EC**, Barnes, WA, Schlegel, RA, Society of Gynecologic Oncologists(SGO) February,1994, presented from podium
14. A Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced of Recurrent Adenocarcinoma of the Endometrium, Sutton, G, Blesing, J, DeMars, L, Moore, D, Burke, D, **Grendys, EC**, Society of Gynecologic Oncologists (SGO), February, 1996, presented from podium
15. Identification of H,K, and N,-ras Point Mutations In Stage IB1 Cervical Carcinoma ,**Grendys, EC**, Barnes, WA, Sparkowski, J, Schlegel, R, New England Association of Gynecologic Oncologists, June,1996, presented from podium
16. Controversies in the Diagnosis and Management of Hereditary Cancer Families, Weitzel, JN, Muto, M, **Grendys, EC**, Ball, HG, New England Association of Gynecologic Oncologists, June 1996, presented from podium
17. Prior Treatment as a Prognostic Indicator For Effective Use of Intraoperative Radiotherapy for Locally Recurrent Gynecologic Malignancies, Bomalaski, J., Fiorica, J, Hoffman, M, **Grendys, EC**, Arango, H, Drake, J, Cavanagh, D, American College of Obstetrics and Gynecology, Armed Forces Annual Meeting, October, 1997, presented from podium
18. Intraoperative lymphoscintigraphy for identification of the sentinel lymph nodes in vulvar cancer, Decesare, SL, Fiorica, JV, **Grendys, EC**, Reintgen, D, Hoffman, MS, Puleo, C, Berman, C, Cavanagh, D, International Congress on the Sentinel Node in Diagnosis and Treatment of Cancer, Amsterdam, the Netherlands, April, 1999, presented as poster

19. Phase II Trial of Topotecan Combined with Cisplatin in Squamous and Non-Squamous Cervical Cancer: Preliminary Results, Fiorica, JV, **Grendys, EC**, Holloway, R, Orr, J, Ndubisi, B, DeCesare, S, LaPolla, J, Boothby, R, Hoffman, M, Arango, H, American Society of Clinical Oncology (ASCO), May, 1999 presented as poster
20. The Efficacy of Low Molecular Weight Heparin's in the Treatment of Venous Thromboembolism in Gynecologic Oncology, Fiorica, J, Green, J, **Grendys, EC**, Hoffman, M, Bomalaski, J, Durfee, J, Hines, J, Kost, E, Cavanagh, D, September, 1999, International Gynecologic Oncology Society, Rome, Italy
21. Phase II Trial of Topotecan Combined with Cisplatin in Squamous and Non-Squamous: Final Results Cervical Cancer, Fiorica, JV, **Grendys, EC**, Holloway, R, Orr, J, Ndubisi, B, DeCesare, S, LaPolla, J, Boothby, R, Hoffman, M, J. Patel, Society of Gynecologic Oncologists(SGO), March, 2001 presented as poster
22. Atrial Natriuretic Peptide and proANP1-30 levels in Gynecologic Malignancy: Rao, PS, Cardosi, RJ, Dietz, JR, Fiorica, JV, **Grendys, E**, Hoffman, MS, American Physiological Society, New Orleans, Louisiana, April, 2000, plenary presentation
23. Value of multilevel sectioning for improved detection of micrometastases in sentinel lymph nodes in invasive squamous cell carcinoma of the vulva, Hakam, A, Nasir, A, Raghuwanshi, R, Smith, PV, Crawley, S, Kaiser, HE, **Grendys, EC**, Fiorica, JF, 92nd Annual Meeting of the United States & Canadian Academy of Pathology, Washington, DC, USA, March, 2003, plenary presentation
24. Randomized Phase III Trial of Cisplatin (P) vs Cisplatin plus Topotecan (T) vs MVAC in Stage IVB, Recurrent or Persistent Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study: Long, H, Bundy, B, **Grendys, EC.**, Benda, J, D. McMeeken, S, Sorosky, J, Miller, D, Eaton, L, Fiorica, J. Society of Gynecologic Oncology (SGO), San Diego, California 2004 plenary presentation
25. Randomized Phase III Trial of Cisplatin (P) vs Cisplatin plus Topotecan (T) vs MVAC in Stage IVB, Recurrent or Persistent Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study: **Grendys, EC.**, Long, H, Bundy, B, Benda, J, D. McMeeken, S, Sorosky, J, Miller, D, Eaton, L, Fiorica, J. International Society of Gynecologic Oncology, Edinburgh, Scotland 2004 plenary presentation
26. Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin versus Gemcitabine/Carboplatin for the Treatment of Platinum Sensitive Recurrent Ovarian Cancer: A Systematic Review: Holloway, RW, **Grendys, EC**, McMeekin, S, Vekeman, F, Lefebvre, P, Society of Gynecologic Oncology, San Antonio, TX Feb., 2009

27. Adherence with National Comprehensive Cancer Network(NCCN) Guidelines Associated with Improved Survival in Ovarian Cancer Patients, A Study of 144,440 Patients from the National Cancer Data Base: A Project from the Society of Gynecologic Oncologists Quality and Outcomes Committee: **Grendys, EC**, Powell, M, Cliby, W, Bristow, R, Al-Hammadi, N, Chen, L, Miller, J, Roland,P, Mutch, D, Commission On Cancer meeting, Chicago, IL, May 13, 2011 Presented as Poster
28. Minimally Invasive hysterectomy rates and surgical outcomes in uterine cancer: A Society of Gynecologic Oncology clinical outcomes registry analysis, Society of Gynecologic Oncology Annual meeting, Toronto, Canada, 2020
29. The Society of Gynecologic Oncology's clinical outcome registry database validation process, Society of Gynecologic Oncology Annual meeting, Toronto, Canada, 2020 Dewdney, SB, Wallace, S, Lachance, JA, **Grendys, EC** et al.
30. Rare Cases not to Miss in Gynecologic Pathology: Two Case Reports, Florida Society of Pathology, 2022; Kauffman, S, Tsakalakis, J, **Grendys, EC**, et at.

Abstracts

1. Long-term in-vitro Culture of Normal Ovarian and Peritoneal Coelomic Epithelium, **Grendys, EC**, Barnes, WA, Schlegel, RA, Gynecologic Oncology;52(1), 122, 1994
2. Identification of H, K, and N- ras Point Mutations in Stage IB Cervical Carcinoma, **Grendys, EC**, Barnes, WA, Sparkowski, J, Schlegel, R, Gynecologic Oncology;52(1),132, 1994
3. Preservation of Multiple Oncogenic Human Papillomavirus Types in Recurrences of Early-Stage Cervical Cancers, Burnett, AF, **Grendys, EC**, Willett, GD, et al. Gynecologic Oncology;52(1), 132, 1994.
- 4 A Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced or Recurrent Adenocarcinoma of the Endometrium, Sutton, GP, Blessing, JA, DeMars, LR, Moore, D, Burke, TW, **Grendys, EC**. Gynecologic Oncology
5. Phase II Trial of Topotecan Combined with Cisplatin in Squamous and Non-Squamous Cervical Cancer: Preliminary Results, Fiorica, JV, **Grendys, EC**, Holloway, R, Orr, J, Ndubisi, B, DeCesare, S, LaPolla, J, Boothby, R, Hoffman, M, Arango, H, Program/Proceedings American Society of Clinical Oncology, 18, 373A, 1999

6. Predictors of Toxicity from Chemotherapy in Older Patients: A Prospective Pilot Study. Extermann, M., Chen, H, Cantor, AB, Corcoran, MB, Meyer, J, **Grendys, EC**, Cavanaugh, D, Antonek, S, Vann, V, Camarata, A, Haley, WB, Balducci, L, Proceedings of American Society of Clinical Oncology, Volume, 19, 2000, page 617a, Abstract Number 2430

7. Utility of Thyroid Transcription Factor-1(TTF-1) in Differentiating Pulmonary Adenocarcinoma from Ovarian or Primary Peritoneal Adenocarcinoma in Women with Malignant Pleural Effusion(MPE), Garland, L, Khor, E, **Grendys, E**, Fiorica, J, Walsh, F, Alberts, M, Rolfe, M, Anderson, W, Ruckdeschel, J. Proceedings of American Society of Clinical Oncology, Volume 19, 2000, page 549a, Abstract Number 2165

8. Phase II Trial of Topotecan Combined with Cisplatin in Squamous and Non-Squamous Cervical Cancer, Fiorica, JV, **Grendys, EC**, Holloway, R, Orr, J, Ndubisi, B, DeCesare, S, LaPolla, J, Boothby, R, Hoffman, M, J. Patel, Society of Gynecologic Oncologists (SGO), March, 2001; Abstract 352

9. Atrial Natriuretic Peptide (ANP) and proANP1-30 levels in Gynecologic Malignancy, Rao,P, Cardosi, R, Dietz, J, Fiorica, J, **Grendys, EC**, American Physiological Society 2002

10. A Population Based Study of BRCA I / II in Ovarian Cancer, Tuya, P, Krischer, J, Holtje, T, Betts, J, Permuth, J, Fiorica, J, **Grendys, EC**, LaPolla, J, Arango, H, Wakeley, K, Hoffman, M, Wilbanks, G, Nicosia, S, Sutphen, R American Society of Human Genetics, 2002, 71(4):250

11. Relation of decline in hemoglobin to cognitive functioning an fatigue during chemotherapy treatment, Jacobsen, PB, Thors, CL, **Grendys,EC**, American Society of Clinical Oncology(ASCO), 2002, 1542

12. Weekly topotecan in platinum resistant ovarian carcinoma, F. Abushahin, **E. C. Grendys**, J. R. Lurain, D. K. Singh, A. W. Rademaker, J. C. Schink, *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 15040

13. Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin versus Gemcitabine/Carboplatin for the Treatment of Platinum Sensitive Recurrent Ovarian Cancer: A Systematic Review: Holloway, RW, **Grendys, EC**, McMeekin, S, Vekeman, F, Lefebvre, P, *Gynecologic Oncology*, 112(2009) S160

14. Minimally Invasive hysterectomy rates and surgical outcomes in uterine cancer: A Society of Gynecologic Oncology clinical outcomes registry analysis, Society of Gynecologic Oncology Annual meeting, Toronto, Canada, 2020 Fader, AN, Dewdney, SB, Wright,JD, **Grendys, EC** et al.
15. The Society of Gynecologic Oncology's clinical outcome registry database validation process, Society of Gynecologic Oncology Annual meeting, Toronto, Canada, 2020 Dewdney, SB, Wallace, S, Lachance, JA, **Grendys, EC** et al.